Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2016-12-23 Board/Management Inform…
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated December 21, 2016. The key content is about the approval of Amended and Restated Performance-Based Restricted Stock Unit Award Agreements with two officers, Nancy Lurker and Deb Jorn. This relates to changes in compensatory arrangements for certain officers. The document does not contain financial statements or earnings data but announces management compensation changes. According to the filing definitions, announcements of changes in senior management or board members fall under Board/Management Information (MANG). The document length is 3574 characters, which is relatively short but contains substantive information about management compensation changes, not just a notice or report publication announcement. Therefore, the appropriate classification is MANG with high confidence.
2016-12-23 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is in Item 8.01 "Other Events," which discusses a letter distributed to investors about recent changes to the company's leadership team and future plans. This indicates the document is primarily an announcement of management changes rather than a full management report or detailed financial report. The letter is attached as an exhibit, but the main document itself is a regulatory filing announcing these changes. There is no detailed financial data or comprehensive management discussion, so it does not qualify as a Management Report (MDA) or Annual Report (10-K). The focus on leadership changes fits the Board/Management Information category (MANG). The document length (6023 characters) is sufficient to contain substantive information, not just a brief announcement, supporting classification as MANG rather than a simple Regulatory Filing (RNS).
2016-12-20 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the departure of a director/officer and detailed voting results from the Annual Meeting of Stockholders, including election of directors and approval of executive compensation and other proposals. This matches the description of announcements related to changes in the company's board or senior management and voting results. Since it includes both management changes and voting results, the primary focus is on the voting results from the shareholder meeting. The document is not a full annual report, audit report, or earnings release, but a regulatory filing reporting specific events. Given the detailed voting results, the best classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (5187 characters) supports it being a full report of voting results rather than a brief announcement. Confidence is high due to the clear presence of voting results and director changes.
2016-12-16 English
FORM 4 SUBMISSION
Director's Dealing
2016-12-14 English
FORM 4 SUBMISSION
Director's Dealing
2016-12-14 English
FORM 4 SUBMISSION
Director's Dealing
2016-12-14 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.